Semaglutide
A GLP-1 receptor agonist that improves glycemic control and reduces appetite.
Written by Anthivera EditorialPending medical review
Updated Regulatory status verified September 1, 2026
FDA-approved
Relevance for women
FDA-approved for weight management (Wegovy) and type 2 diabetes (Ozempic); widely prescribed via telehealth.
Recent research mentioning Semaglutide
Pulled from our weekly editorial digest of PubMed, FDA, NEJM, JAMA, and Endpoints — cite-worthy entries only.
Dapagliflozin Alone or Combined With Semaglutide: Cardiovascular and Renal Outcomes Among Patients With Type 2 Diabetes Mellitus in a 6-Month Real-World Retrospective Cohort Study in Saudi Arabia.
PubMed (women's-health + peptide query) · 2026 Aug · digested 2026-09-28
Sex and Socioeconomic Differences in the Initiation of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Nationwide Cohort Study.
PubMed (women's-health + peptide query) · 2026 Sep 20 · digested 2026-09-21
Compounded GLP-1 Drugs Remain Prevalent After Drug Shortage
JAMA Internal Medicine · digested 2026-09-07
Glucagon-like Peptide-1 receptor agonist use is associated with decreased risk of periprosthetic joint infection following total knee arthroplasty: A laterality-verified propensity matched comparison.
PubMed (women's-health + peptide query) · 2026 Sep-Dec · digested 2026-09-07
Estimating Eligibility for GLP-1 Receptor Agonists for Chronic Weight Management and Cardiovascular Disease in Australia: Cross-Sectional Analysis of National Health Survey Data.
PubMed (women's-health + peptide query) · 2026 Aug · digested 2026-08-17
Where the evidence sits
Anthivera’s calibrated five-tier scale — what the strongest evidence on Semaglutide actually supports today.
- Preclinical
- Limited clinical
- Multiple human studies
- Phase 3
- FDA-approvedSemaglutide
FDA-approved: FDA-approved for the indication claimed.
Questions to bring to a consult
- 01What evidence is there for Semaglutide in women specifically — and does that include perimenopausal or postmenopausal cohorts?
- 02What is the current FDA regulatory status, and which compounding pharmacy will my prescription go through?
- 03What baseline labs do you require before starting, and how often do you monitor?
- 04What are the realistic timelines and what does “not working for you” look like in practice?
Articles on Semaglutide
GLP-1 and Hair Loss in Women: What the Ads Get Backwards
Instagram ads increasingly pair GLP-1 medications with hair benefits. The evidence points the other way — GLP-1s are associated with hair loss, and the risk is higher in women. What's actually happening, why, and what to do about it.
GLP-1 Medications for Women: What the Research Actually Says
A grounded look at GLP-1 medications — semaglutide, tirzepatide, and the newer agents in trials — for women specifically: what the 2026 evidence shows, the muscle-and-bone question, the sourcing and regulatory picture, and what these drugs do not do.
Providers that offer Semaglutide
- 4.5/5
Evergreen Women's Health
Strongest fit for perimenopausal women seeking continuity of care — pairs hormone testing with peptide protocols.
- 4.0/5
Canopy Telehealth Clinic
Broad catalog and broad geographic reach; longer intake process but thorough lab work.
See the full provider comparison for all peptides side by side.